Compare Domino's Pizza, Inc. (DPZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Domino's Pizza, Inc. trades at $313.92 (market cap $10.31B), while State Street SPDR S&P Biotech ETF trades at $155.27. The key difference: Domino's Pizza, Inc. pays a 2.57% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Domino's Pizza, Inc. nearer its low. Which is the better fit depends on your goals.
| DPZ | XBI | |
|---|---|---|
Market Cap | $10.31B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $485.53 | $164.28 |
52-Week Low | $282.89 | $85.16 |
Enterprise Value | $15.21B | — |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.85, up 3.47% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $4.13, missing expectations, but maintains strong profitability with a net margin of 11.89%. Recent news includes CEO succession and new product launches, while analyst consensus remains bullish with a $380.31 price target.
DPZ offers steady growth and a 2.66% dividend yield, but faces risks from slowing same-store sales and high debt. The stock's valuation at 17.84x P/E is reasonable, yet competitive pressures and macroeconomic headwinds warrant caution. Upside potential exists if Q2 earnings beat expectations and new leadership reinvigorates growth.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
